Overview A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia Status: NOT_YET_RECRUITING Trial end date: 2027-05-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the efficacy, safety, PK, and PD of atumelnant in adults with classic CAH due to 21-OHD.Phase: PHASE3 Details Lead Sponsor: Crinetics Pharmaceuticals Inc.